7-氯-5-硝基二氢吲哚 | 196205-08-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 7-氯-5-硝基二氢吲哚
• 英文名称: 7-chloro-5-nitroindoline
• 英文别名: 7-chloro-5-nitro-2,3-dihydro-1H-indole
• CAS: 196205-08-0
• 化学式: C₈H₇ClN₂O₂
• 分子量: 198.609
• InChiKey: MDFIYXAUHLQZBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-氯-5-硝基二氢吲哚 在 氧化锰 氧化锰 、 silica gel 、 乙酸乙酯 、 正己烷 作用下， 以 乙酸乙酯 为溶剂， 反应 15.0h， 以to give the title compound (1.92 g) as a pale-brown powder的产率得到7-氯-5-硝基-1H-吲哚
  参考文献：
  名称：

  FUSED HETEROCYCLIC COMPOUND

  摘要：

  本发明提供了一种化合物，其表示为以下式子：其中，R1a是氢原子，R2a是一个C1-6烷基，被一个表示为—NR6a—CO—（CH2）n—SO2—的基团取代，该基团可选地卤代C1-4烷基，其中n是1至4的整数，R6a是氢原子或C1-4烷基，—（CH2）n—可选地被C1-4烷基取代，R3a是氢原子或C1-6烷基，R4a是卤原子或C1-6烷基，R5a是卤原子或C1-6烷基，Xa是氢原子或卤原子，或其盐。本发明的化合物具有卓越的酪氨酸激酶抑制作用，高度安全，并且作为药物产品完全令人满意。

  公开号：

  US20100216788A1
• 作为产物：
  描述：

  5-硝基二氢吲哚 在 氯 作用下， 以 溶剂黄146 为溶剂， 生成 7-氯-5-硝基二氢吲哚
  参考文献：
  名称：

  5- and 6-(2-imidazolin-2-ylamino) and

  摘要：

  这项发明涉及选择性作用于克隆人类α2受体的吲哚和苯并噻唑化合物。该发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外，该发明包括使用这些化合物降低眼内压、治疗老花眼、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁，以及用作认知增强剂和眼部血管收缩剂。该发明还提供一种包含上述定义化合物的治疗有效量和药用可接受载体的药物组合物。

  公开号：

  US05677321A1

文献信息

• Novel indole and benzothiazole derivatives
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：US20020049239A1

  公开（公告）日：2002-04-25

  This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及新型的吲哚和苯并噻唑化合物，这些化合物对克隆的人类α2受体具有选择性。本发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外，本发明还包括使用这些化合物降低眼内压、治疗老视、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁以及用作认知增强剂和眼部血管收缩剂。本发明还提供了一种药物组合物，其中包括上述定义的化合物的治疗有效量和药学可接受的载体。
• Benzimidazoles and benzothiazoles and uses thereof
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：US20030105147A1

  公开（公告）日：2003-06-05

  This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及一种新型的吲哚和苯并噻唑化合物，其对克隆人类α2受体具有选择性。本发明还涉及使用这些化合物的用途，适用于任何需要使用α2激动剂的情况。具体来说，这包括用作镇痛剂、镇静剂和麻醉剂。此外，本发明还包括使用这些化合物降低眼压、老视、治疗偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁以及用作认知增强剂和眼部血管收缩剂。本发明还提供了一种包含上述定义化合物的治疗有效量和药学上可接受的载体的药物组合物。
• Substituted indoles and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06040451A1

  公开（公告）日：2000-03-21

  This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及一种新型的吲哚和苯并噻唑化合物，其对克隆的人类α2受体具有选择性。本发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外，本发明还包括使用这些化合物降低眼压、治疗老视眼、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞和尿失禁，以及用作认知增强剂和眼部血管收缩剂。本发明还提供一种药物组合物，其中包括上述定义的化合物的治疗有效量和药学上可接受的载体。
• Indole and benzothiazole derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06498177B2

  公开（公告）日：2002-12-24

  This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及新颖的吲哚和苯并噻唑化合物，这些化合物对克隆的人α2受体具有选择性。本发明还涉及这些化合物的用途，用于任何需要使用α2激动剂的适应症。具体来说，包括用作镇痛剂、镇静剂和麻醉剂。此外，本发明还包括使用这些化合物降低眼压、治疗老视、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁以及用作认知增强剂和眼部血管收缩剂。本发明还提供一种药物组合物，包括上述定义的化合物的治疗有效量和药学上可接受的载体。
• NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：EP0900080A1

  公开（公告）日：1999-03-10